Manion C V, Lalka D, Baer D T, Meyer M B
J Pharm Sci. 1977 Jul;66(7):981-4. doi: 10.1002/jps.2600660719.
Plasma procainamide concentrations following the administration of 500 mg of procainamide hydrochloride via intravenous infusion, conventional capsules, and sustained-release tablets were compared in 11 healthy male volunteers. Two-compartment open modeling of the plasma levels from the intravenous infusion experiments yielded mean Kel, k12, and k21 values of 0.0162, 0.0542, and 0.0233 min-1, respectively. The bioavailability of the oral preparations (versus intravenous) averaged 83% for the capsule and 79% for the sustained-release tablet. Calculations using a previously reported method suggested that absorption was a first-order process with mean ka's of 0.0336 and 0.0039 min-1 for the capsule and sustained-release tablet, respectively. The sustained-release formulation exhibited delayed release and adequate bioavailability.
在11名健康男性志愿者中比较了通过静脉输注、常规胶囊和缓释片给予500毫克盐酸普鲁卡因胺后血浆普鲁卡因胺浓度。静脉输注实验血浆水平的二室开放模型得出平均消除速率常数(Kel)、中央室向周边室转运速率常数(k12)和周边室向中央室转运速率常数(k21)分别为0.0162、0.0542和0.0233分钟⁻¹。口服制剂(相对于静脉注射)的生物利用度,胶囊平均为83%,缓释片为79%。使用先前报道的方法进行的计算表明,吸收是一级过程,胶囊和缓释片的平均吸收速率常数(ka)分别为0.0336和0.0039分钟⁻¹。缓释制剂表现出延迟释放和足够的生物利用度。